Cholestane-3β, 5α, 6β-triol Suppresses Proliferation, Migration, and Invasion of Human Prostate Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lin, Ching Yu ^a   Huo, Chieh ^a,b   Kuo, Li Kuo ^c   Hiipakka, Richard A ^d   Jones, Richard Baker ^d,e   Lin, Hui Ping ^a   Hung, Yuwen ^a,f   Su, Liang Cheng ^a   Tseng, Jen Chih ^a,f   Kuo, Ying Yu ^a   Wang, Yu Ling ^a,f   Fukui, Yasuhisa ^a   Kao, Yung Hsi ^b   Kokontis, John M ^d   Yeh, Chien Chih ^g   Chen, Linyi ^f   Yang, Shiaw Der ^f   Fu, Hsiao Hui ^f   Chen, Ya Wen ^a   Tsai, Kelvin K C ^a   Chang, Jang Yang ^a   Chuu, Chih Pin ^a,h,i   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^g TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ALPHA TUBULIN; BETA ACTIN; CHOLESTANE 3BETA 5 ALPHA 6BETA TRIOL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FOCAL ADHESION KINASE; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; OXYSTEROL; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2; SERINE; THREONINE; TRANSCRIPTION FACTOR SLUG; TYROSINE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACTINS; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTANOLS; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; MALE; MICE; NEOPLASM INVASIVENESS; ORPHAN NUCLEAR RECEPTORS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEOME; PROTO-ONCOGENE PROTEINS C-AKT; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; TUBULIN; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84878980505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065734     Document Type: Article

References (66)

1. Hellerstedt BA, Pienta KJ, (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154-179.
2. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, et al. (2011) Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 18: 63.
3. Gilligan T, Kantoff PW (2002) Chemotherapy for prostate cancer. Urology 60: 94-100; discussion 100.
4. Jusakul A, Yongvanit P, Loilome W, Namwat N, Kuver R, (2011) Mechanisms of oxysterol-induced carcinogenesis. Lipids Health Dis 10: 44.
5. Dufour J, Viennois E, De Boussac H, Baron S, Lobaccaro JM (2012) Oxysterol receptors, AKT and prostate cancer. Curr Opin Pharmacol.
6. Chuu CP, (2011) Modulation of liver X receptor signaling as a prevention and therapy for colon cancer. Med Hypotheses 76: 697-699.
7. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, et al. (2006) Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 66: 6482-6486.
8. Chuu CP, Chen RY, Hiipakka RA, Kokontis JM, Warner KV, et al. (2007) The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochem Biophys Res Commun 357: 341-346.
9. Chuu CP, Kokontis JM, Hiipakka RA, Liao S, (2007) Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 14: 543-553.
10. Chuu CP, Lin HP, (2010) Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 30: 3643-3648.
11. Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S, (2004) Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 64: 7686-7689.
12. Ayala-Torres S, Zhou F, Thompson EB, (1999) Apoptosis induced by oxysterol in CEM cells is associated with negative regulation of c-myc. Exp Cell Res 246: 193-202.
13. Biasi F, Chiarpotto E, Sottero B, Maina M, Mascia C, et al. (2013) Evidence of cell damage induced by major components of a diet-compatible mixture of oxysterols in human colon cancer CaCo-2 cell line. Biochimie 95: 632-640.
14. Kang KA, Chae S, Lee KH, Park MT, Lee SJ, et al. (2005) Cytotoxic effect of 7beta-hydroxycholesterol on human NCI-H460 lung cancer cells. Biol Pharm Bull 28: 1377-1380.
15. Bosisio E, Galli G, Nicosia S, Galli Kienle M, (1976) Catabolism of cholesterol by bovine adrenal-cortex enzymes: in vitro formation of oxygenated sterols and side-chain cleavage products. Eur J Biochem 63: 491-497.
16. Watabe T, Sawahata T, (1979) Biotransformation of cholesterol to cholestane-3beta,5alpha,6beta-triol via cholesterol alpha-epoxide (5alpha,6alpha-epoxycholestan-3beta-ol) in bovine adrenal cortex. J Biol Chem 254: 3854-3860.
17. Chevrier N, Mertins P, Artyomov MN, Shalek AK, Iannacone M, et al. (2011) Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits. Cell 147: 853-867.
18. Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB, (2010) Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 7: 148-155.
19. Hause RJ, Kim HD, Leung KK, Jones RB, (2011) Targeted protein-omic methods are bridging the gap between proteomic and hypothesis-driven protein analysis approaches. Expert Rev Proteomics 8: 565-575.
20. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, et al. (2011) Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 33: 1774-1782.
21. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S, (2009) Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 275: 86-92.
22. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S, (2005) Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65: 2082-2084.
23. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, et al. (2011) Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci 102: 2022-2028.
24. Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause RJ Jr, et al. (2012) Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. Cancer Prev Res (Phila) 5: 788-797.
25. Kokontis J, Takakura K, Hay N, Liao S, (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-1573.
26. Kokontis JM, Hay N, Liao S, (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
27. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, et al. (2005) Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65: 287-298.
28. Lin HP, Jiang SS, Chuu CP, (2012) Caffeic Acid Phenethyl Ester Causes p21 Induction, Akt Signaling Reduction, and Growth Inhibition in PC-3 Human Prostate Cancer Cells. PLoS One 7: e31286.
29. Lin HP, Kuo LK, Chuu CP, (2011) Combined Treatment of Curcumin and Small Molecule Inhibitors Suppresses Proliferation of A549 and H1299 Human Non-Small-Cell Lung Cancer Cells. Phytother Res 26: 122-126.
30. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF, (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281.
31. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
32. Sarker D, Reid AH, Yap TA, de Bono JS, (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15: 4799-4805.
33. Lin HP, Lin CY, Liu CC, Su LC, Huo C, et al. (2013) Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. International journal of molecular sciences 14: 5264-5283.
34. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236.
35. Palladini G, Finardi G, Bellomo G, (1996) Disruption of actin microfilament organization by cholesterol oxides in 73/73 endothelial cells. Exp Cell Res 223: 72-82.
36. Palladini G, Finardi G, Bellomo G, (1996) Modifications of vimentin filament architecture and vimentin-nuclear interactions by cholesterol oxides in 73/73 endothelial cells. Exp Cell Res 223: 83-90.
37. Moriel P, Sevanian A, Ajzen S, Zanella MT, Plavnik FL, et al. (2002) Nitric oxide, cholesterol oxides and endothelium-dependent vasodilation in plasma of patients with essential hypertension. Braz J Med Biol Res 35: 1301-1309.
38. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, et al. (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116: 1406-1418.
39. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, et al. (2001) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 20: 333-349.
40. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583.
41. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, et al. (2008) Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68: 2479-2488.
42. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, et al. (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12: 559-571.
43. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, et al. (2006) Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66: 1664-1673.
44. Ao M, Williams K, Bhowmick NA, Hayward SW, (2006) Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66: 8007-8016.
45. Beach S, Tang H, Park S, Dhillon AS, Keller ET, et al. (2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27: 2243-2248.
46. Sakamoto S, McCann RO, Dhir R, Kyprianou N, (2010) Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Research 70: 1885-1895.
47. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR, (1999) Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Research 59: 1655-1664.
48. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, et al. (2010) Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 29: 1293-1302.
49. Franzen CA, Amargo E, Todorovic V, Desai BV, Huda S, et al. (2009) The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer prevention research 2: 830-841.
50. Liu CC, Hsu JM, Kuo LK, Chuu CP, (2013) Caffeic acid phenethyl ester as an adjuvant therapy for advanced prostate cancer. Medical hypotheses 80: 617-619.
51. Coffer PJ, Jin J, Woodgett JR, (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335 (Pt 1): 1-13.
52. Gonzalez E, McGraw TE, (2009) The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8: 2502-2508.
53. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
54. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
55. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
56. Vellaichamy A, Dezso Z, JeBailey L, Chinnaiyan AM, Sreekumar A, et al. (2010) "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 5: e10936.
57. Edwards J, Krishna NS, Witton CJ, Bartlett JM, (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281.
58. Grad JM, Dai JL, Wu S, Burnstein KL, (1999) Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 13: 1896-1911.
59. Umekita Y, Hiipakka RA, Kokontis JM, Liao S, (1996) Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 93: 11802-11807.
60. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, et al. (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101: 519-532.
61. Elledge SJ, Harper JW, (1994) Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852.
62. Carrano AC, Eytan E, Hershko A, Pagano M, (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1: 193-199.
63. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H, (1999) p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9: 661-664.
64. Cantwell H, Devery R, (1998) The response of the antioxidant defense system in rat hepatocytes challenged with oxysterols is modified by Covi-ox. Cell Biol Toxicol 14: 401-409.
65. Panagiotou S, Bakogeorgou E, Papakonstanti E, Hatzoglou A, Wallet F, et al. (1999) Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements. J Cell Biochem 73: 204-211.
66. Nolasco S, Bellido J, Goncalves J, Zabala JC, Soares H, (2005) Tubulin cofactor A gene silencing in mammalian cells induces changes in microtubule cytoskeleton, cell cycle arrest and cell death. FEBS letters 579: 3515-3524.